Literature DB >> 15647415

The influence of norfloxacin and metronidazole on the disposition of mycophenolate mofetil.

Odin J Naderer1, Robert E Dupuis, Erin L Heinzen, Kamonthip Wiwattanawongsa, Mark W Johnson, Philip C Smith.   

Abstract

The objective of this study was to investigate the effect of concurrent antibiotic administration on the disposition of mycophenolic acid (MPA) and mycophenolic acid glucuronide (MPAG) after oral administration of mycophenolate mofetil (MMF) in healthy subjects. Eleven healthy subjects were enrolled. The study was divided into 4 treatment periods. Subjects received MMF as a single oral 1-g dose alone and were then randomized to 3 antibiotic treatment periods. The 3 periods included norfloxacin, metronidazole, and a combination of norfloxacin and metronidazole. Antibiotic treatment was started 3 days prior to each MMF pharmacokinetic study day and was given for a total of 5 days. On day 4 of each antibiotic phase, subjects received a single 1-g oral dose of MMF. Plasma and urine samples were obtained over 48 hours after the MMF dose in all treatment periods and were quantitatively measured for MPA and MPAG. Pharmacokinetic parameters for MPA and MPAG were determined for all periods. Compared to MMF alone, the area under the plasma concentration versus time curve (AUC) of MPA was reduced by an average of 10%, 19%, and 33% when given with norfloxacin, metronidazole, and norfloxacin plus metronidazole, respectively. The AUC of MPAG was also reduced on average by 10%, 27%, and 41% in the corresponding periods. The combination of norfloxacin and metronidazole significantly reduced the AUC of MPA and MPAG in healthy subjects. This likely occurs as a result of reduced enterohepatic recirculation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15647415     DOI: 10.1177/0091270004271555

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  15 in total

1.  Population pharmacokinetics of mycophenolic acid and metabolites in patients with glomerulonephritis.

Authors:  Wai-Johnn Sam; Melanie S Joy
Journal:  Ther Drug Monit       Date:  2010-10       Impact factor: 3.681

Review 2.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

3.  Population pharmacokinetics and Bayesian estimators for intravenous mycophenolate mofetil in haematopoietic stem cell transplant patients.

Authors:  Marc Labriffe; Julien Vaidie; Caroline Monchaud; Jean Debord; Pascal Turlure; Stephane Girault; Pierre Marquet; Jean-Baptiste Woillard
Journal:  Br J Clin Pharmacol       Date:  2020-02-28       Impact factor: 4.335

Review 4.  Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.

Authors:  Jeannine S McCune; Meagan J Bemer; Janel Long-Boyle
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

5.  Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors.

Authors:  Adam Frymoyer; Davide Verotta; Pamala Jacobson; Janel Long-Boyle
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

6.  Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies.

Authors:  Zheng Jiao; Jian-Yong Zhong; Ming Zhang; Xiao-Jin Shi; Yun-Qiu Yu; Wei-Yue Lu
Journal:  Eur J Clin Pharmacol       Date:  2006-11-09       Impact factor: 2.953

7.  Population pharmacokinetics of mycophenolic acid and its main glucuronide metabolite: a comparison between healthy Chinese and Caucasian subjects receiving mycophenolate mofetil.

Authors:  Jing Ling; Jun Shi; Qiudi Jiang; Zheng Jiao
Journal:  Eur J Clin Pharmacol       Date:  2014-10-21       Impact factor: 2.953

8.  Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil.

Authors:  H Li; D E Mager; B M Sandmaier; D G Maloney; M J Bemer; J S McCune
Journal:  J Clin Pharmacol       Date:  2013-02-04       Impact factor: 3.126

Review 9.  Clinical Pharmacokinetics of Mycophenolic Acid in Hematopoietic Stem Cell Transplantation Recipients.

Authors:  Daping Zhang; Diana S-L Chow
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-04       Impact factor: 2.441

Review 10.  Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions.

Authors:  Dirk R J Kuypers
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.